Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

593.87 +11.53 (+1.98%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Madrigal Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) Beats Q2 2025 Revenue Estimates and Narrows Losses on Strong Rezdiffra Sales ↗
Madrigal Pharmaceuticals (MDGL) beats Q2 2025 revenue estimates with $212.8M, driven by strong Rezdiffra sales, narrowing losses. Stock rises 12.8% pre-market. 
Via Chartmill
News headline image
Earnings Scheduled For August 5, 2025 ↗
 
Via Benzinga
News headline image
European Advisory Panel Backs Conditional Approval For Madrigal's Fatty Liver Disease Drug ↗
Rezdiffra wins CHMP backing for conditional EU approval in MASH with fibrosis; decision from European Commission expected in August. 
Via Benzinga
News headline image
5 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
2 Monster Stocks in the Making to Buy Now and Hold for 10 Years ↗
Via The Motley Fool
News headline image
Madrigal Pharma Short Interest Reaches 4-Month High: Retail Investors Still Bullish On Stock ↗
Despite soaring short interest, retail sentiment remains bullish, with investors optimistic about the company’s positive trial results and the continued demand for its FDA-approved treatment,... 
Via Stocktwits
Topics Death
News headline image
Earnings Scheduled For May 1, 2025 ↗
 
Via Benzinga
News headline image
Why Madrigal Pharmaceuticals Stock Is Soaring Today ↗
Via The Motley Fool
News headline image
Earnings Scheduled For February 26, 2025 ↗
 
Via Benzinga
News headline image
Why Madrigal Pharmaceuticals Stock Is Sinking Today ↗
Via The Motley Fool
News headline image
Uncovering Potential: Madrigal Pharmaceuticals's Earnings Preview ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Workday, ACM Research, ZoomInfo Technologies, CEVA, Intuit And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Earnings Preview For Madrigal Pharmaceuticals ↗
 
Via Benzinga
News headline image
Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis ↗
Madrigal's Rezdiffra showed significant liver stiffness reduction in MASH cirrhosis. The company also beat Q4 earnings and revenue expectations. 
Via Benzinga
News headline image
8 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Why Madrigal Pharmaceuticals Stock Was Plummeting This Week ↗
Via The Motley Fool
News headline image
Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease. 
Via MarketBeat
News headline image
Top 3 Health Care Stocks That May Dip This Month ↗
 
Via Benzinga
News headline image
Billionaire Ken Griffin Invested $93 Million of Citadel's Portfolio in a Stock That Could Rocket 105% Higher, According to a Wall Street Analyst ↗
Via The Motley Fool
News headline image
3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move ↗
Via The Motley Fool
News headline image
MDGL: A Promising Play In The Weight Loss Drug Space ↗
The launch of Madrigal Pharmaceuticals Inc.’s NASH drug Rezdiffra exceeded all expectations in the recent quarterly earnings release. The stock rose more than 50% in a few days – and the company now... 
Via Talk Markets
Topics Stocks / Equities
News headline image
1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More ↗
There's a bright future ahead for this company. 
Via The Motley Fool
News headline image
Apple Satellite Connectivity Provider Globalstar And Timberland Parent V.F Corp Are Among Top 7 Mid Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio? ↗
Top mid-cap stock performers: MDGL (+51.70%), PRCT (+34.20%), GSAT (+33.98%), WGS (+31.17%), NXT (+25.91%), VFC (+25.82%), OMCL (+23.22%). 
Via Benzinga
News headline image
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH ↗
Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Is Madrigal Pharmaceuticals Stock a Buy? ↗
The biotech could be worth a lot more in 10 years. 
Via The Motley Fool
News headline image
This 1 Setback for Novo Nordisk Is Bullish for Madrigal Pharmaceuticals Stock ↗
One player's minor pain is another's moderate gain. 
Via The Motley Fool
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.